Population Pharmacokinetics of Bedaquiline (TMC207), a Novel Antituberculosis Drug

Sarah McLeay, Peter Vis, Rolf P. G. van Heeswijk, +1

Antimicrobial Agents and Chemotherapy

Pulmonary TuberculosisPharmacokinetic ModelingHealthy SubjectsPharmacologyAntimicrobial Resistance +13

Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents

Stéphane Blanche, Rosa Bologna, Pedro Cahn, +8

AIDS

Pharmacokinetics and Pharmacodynamics of the Non-Nucleoside Reverse-Transcriptase Inhibitor Etravirine in Treatment-Experienced HIV-1-Infected Patients

Thomas N. Kakuda, Janet R. Wade, Eric Snoeck, +10

Clinical Pharmacology & Therapeutics

Population pharmacokinetic characterization of <scp>BAY</scp> 81‐8973, a full‐length recombinant factor <scp>VIII</scp>: lessons learned ‒ importance of including samples with factor <scp>VIII</scp> levels below the quantitation limit

Dirk Garmann, Sarah McLeay, Anita Shah, +3

Haemophilia

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial

Thomas N. Kakuda, Vanitha Sekar, Peter Vis, +5

AIDS Research and Treatment

Characterization of the pharmacodynamics of several antiepileptic drugs in a direct cortical stimulation model of anticonvulsant effect in the rat.

A. Hoogerkamp, Peter Vis, Meindert Danhof, +1

Journal of Pharmacology and Experimental Therapeutics

Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral‐naïve, HIV‐1‐infected patients in ECHO and THRIVE

HM Crauwels, Erno van Schaick, R. Van Heeswijk, +3

Journal of the International AIDS Society

Treatment And PreventionMedicineHuman RetrovirusImmunologyHiv Infection +12

Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop

Klaus Romero, Vikram Sinha, Sandra R. B. Allerheiligen, +21

Journal of Pharmacokinetics and Pharmacodynamics

Fda-c-path-isop 2013EngineeringHealth PolicyMedical Product DevelopmentOutcomes Research +8

Pharmacokinetics and short-term safety of the selective NOS inhibitor 2-iminobiotin in asphyxiated neonates treated with therapeutic hypothermia

Laurent M. A. Favié, Cacha Peeters‐Scholte, Anouk de Bakker, +6

Pediatric Research

NeonatologyMedicineSelective Nos InhibitorPharmacotherapyAsphyxiated Neonates +2

Pharmacokinetic (PK) and pharmacodynamic analyses of once‐ and twice‐daily darunavir/ritonavir (DRV/r) in the ODIN trial

V. Sekar, Guy De La Rosa, Tom Van de Casteele, +3

Journal of the International AIDS Society

Drug InteractionsPharmacokinetic ModelingTreatment And PreventionHuman RetrovirusPharmacology +13